Breast Cancer Relapse Prevented For Up To 8 Years By Aromatase Inhibitor Letrozole
 

Results from the longest-running trial comparing tamoxifen with the aromatase inhibitor letrozole show unequivocally that letrozole has withstood the test of time and continues to prevent breast cancer recurrences and reduce the risk of death in post-menopausal women with hormone receptor-positive early breast cancer...

More...